Literature DB >> 24533548

Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.

Shin-Ya Kawashiri1, Kazuhiko Arima, Takahisa Suzuki, Yoshikazu Nakashima, Yoshiro Horai, Akitomo Okada, Mami Tamai, Hideki Nakamura, Atsushi Kawakami.   

Abstract

A 63-year-old male Japanese rheumatoid arthritis (RA) patient, in whom treatment with infliximab and methotrexate (MTX) had once led to drug-free remission, experienced a disease flare in July 2010. He was retreated with a combination of adalimumab and MTX, and clinical remission was achieved in 3 months. In contrast, power Doppler signals by ultrasonography with increased serum vascular endothelial growth factor still remained after he achieved sustained clinical remission, whereas no radiographic progression has been found.

Entities:  

Keywords:  Adalimumab; Angiopoietin-2; Musculoskeletal ultrasonography; Rheumatoid arthritis; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2014        PMID: 24533548     DOI: 10.3109/14397595.2013.874736

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  1 in total

1.  Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled.

Authors:  Shin-Ya Kawashiri; Keita Fujikawa; Ayako Nishino; Akitomo Okada; Toshiyuki Aramaki; Toshimasa Shimizu; Masataka Umeda; Shoichi Fukui; Takahisa Suzuki; Tomohiro Koga; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Akinari Mizokami; Hideki Nakamura; Tomoki Origuchi; Yukitaka Ueki; Kiyoshi Aoyagi; Takahiro Maeda; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2017-05-25       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.